The FDA peptide reclassification is the most significant regulatory development for medical practices interested in peptide therapy since the original Category 2 designations. In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides currently classified as Category 2 are expected to move back to Category 1, which would make them eligible for compounding with a physician’s prescription.
The formal FDA rule change has not yet been published. This article covers what has been announced, which peptides are expected to be affected, and how medical practices can prepare.
What Is the FDA Peptide Reclassification?
The FDA maintains a list of bulk drug substances and categorizes them for compounding eligibility. Category 1 substances can be compounded by pharmacies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Category 2 substances are under evaluation and are not eligible for compounding.
In recent years, the FDA placed 19 peptides into Category 2, effectively removing them from the compounding market. On February 27, 2026, HHS Secretary RFK Jr. announced during a public appearance that approximately 14 of those peptides would be moved back to Category 1. This announcement signaled a major policy shift, but the formal rulemaking process is still underway.
For medical practices, this expected change opens the door to offering peptide therapy programs using compounded formulations prescribed by the practice’s own physicians.
Which Peptides May Return to Category 1?
Based on the February 2026 announcement, the following peptides are expected to move from Category 2 back to Category 1:
| Peptide | Expected New Status | Common Therapeutic Uses |
|---|---|---|
| BPC-157 | Category 1 | Tissue repair, gut health, musculoskeletal recovery |
| Thymosin Alpha-1 | Category 1 | Immune modulation, chronic infection support |
| TB-500 (Thymosin Beta-4) | Category 1 | Tissue repair, wound healing, inflammation |
| CJC-1295 | Category 1 | Growth hormone secretion, body composition |
| Ipamorelin | Category 1 | Growth hormone release, recovery, anti-aging |
| AOD-9604 | Category 1 | Fat metabolism, body composition |
| GHK-Cu | Category 1 | Skin health, wound healing, collagen production |
| MOTS-c | Category 1 | Metabolic regulation, exercise performance |
| Selank | Category 1 | Cognitive function, anxiolytic properties |
| Semax | Category 1 | Neuroprotection, cognitive enhancement |
| KPV | Category 1 | Anti-inflammatory, gut health |
| DSIP (Delta Sleep-Inducing Peptide) | Category 1 | Sleep regulation |
| Kisspeptin-10 | Category 1 | Hormonal regulation |
| GHRP-6 | Category 1 | Growth hormone release |
Peptides That May Remain Restricted
Not all Category 2 peptides are expected to return to Category 1. The following peptides may remain under restricted status:
- Melanotan II - Tanning peptide with safety concerns
- GHRP-2 - Growth hormone releasing peptide under continued evaluation
- LL-37 - Antimicrobial peptide with complex safety profile
- PEG-MGF - Pegylated mechano growth factor
- Dihexa - Cognitive peptide with limited safety data
Practices should monitor FDA announcements for the official final rule, which will confirm exactly which peptides receive Category 1 status. The FDA’s compounding page is the best primary source for updates.
What Does This Mean for Medical Practices?
The expected reclassification creates a meaningful opportunity for practices across several specialties.
The Opportunity Window
Patient demand for peptide therapy has grown significantly over the past several years, even during the Category 2 restrictions. Practices that establish peptide therapy programs early will be positioned to capture this demand as the regulatory picture becomes clearer.
The timing is particularly relevant because GLP-1 compounding is facing new restrictions. The FDA declared the semaglutide shortage over in February 2025, which removed the legal basis for most compounded semaglutide. The agency has also proposed permanently barring 503B facilities from bulk compounding semaglutide, tirzepatide, and liraglutide. Practices that rely solely on compounded GLP-1 medications need to consider diversifying their programs.
Adding peptide therapy alongside an existing GLP-1 program gives practices a complementary cash-pay revenue stream that is less dependent on any single medication’s compounding status.
Which Practice Types Benefit Most
- Functional medicine practices already have patient populations interested in peptide protocols for recovery, immune support, and longevity
- Anti-aging and longevity clinics can add peptides as part of full wellness programs
- Med spas expanding beyond aesthetics into regenerative medicine and body composition
- Primary care practices looking to add a cash-pay specialty program for the first time
- Practices currently running GLP-1 weight loss programs that want to diversify their offerings
How to Prepare Your Practice for Peptide Therapy
Even before the formal FDA rule is published, practices can take several steps to be ready to launch quickly once the reclassification is finalized.
Step 1: Understand the Regulatory Landscape
Review the current FDA category designations for the peptides you plan to offer. Monitor the FDA’s bulk drug substance list for updates. Understand the difference between 503A (patient-specific prescriptions) and 503B (outsourcing facility) compounding pathways, as this affects your pharmacy partner selection.
Step 2: Choose Compounding Pharmacy Partners
Identify pharmacies with established peptide formularies. Key factors to evaluate:
- 503A vs. 503B status and which pathway aligns with your prescribing model
- Peptide formulary breadth - does the pharmacy carry the peptides you want to prescribe?
- Fulfillment model - direct-to-patient shipping vs. ship-to-practice
- Quality certifications - PCAB accreditation, state licensing, quality testing protocols
- Integration capabilities - can you send prescriptions electronically or does it require manual processes?
Several compounding pharmacies already have peptide therapy formularies, including Empower Pharmacy, Olympia Pharmacy, Strive Pharmacy, and Belmar Pharma Solutions.
Step 3: Set Up Patient Intake and Clinical Workflows
A peptide therapy program needs structured clinical workflows:
- Patient intake forms covering medical history, current medications, contraindications, and treatment goals
- Clinical screening protocols to identify patients who are appropriate candidates
- Informed consent documentation specific to peptide therapy
- Prescribing protocols for dosing, administration routes, and treatment duration
- Follow-up schedules for monitoring and dose adjustments
Step 4: Plan Your Prescribing and Documentation Process
Peptide prescribing involves clinical review at multiple stages. Your workflow should include:
- Patient evaluation (in-person or telehealth, depending on state requirements)
- Lab work review when clinically indicated
- Clinical decision-making and prescription creation
- Pharmacy routing and fulfillment tracking
- Patient follow-up and treatment monitoring
Practices using platforms with AI-assisted clinical review can streamline this process. AI triage can flag contraindications, summarize patient histories, and prepare clinical summaries for physician review, reducing the time spent on administrative documentation while keeping the physician in full clinical control.
Step 5: Review State-Level Regulations
Peptide prescribing regulations vary by state. Before launching, verify with your state medical board and state board of pharmacy:
- Your state’s prescriptive authority rules for compounded medications
- Any state-specific compounding regulations that may apply
- Telehealth prescribing rules if you plan to offer virtual consultations
- State board of pharmacy regulations for receiving compounded medications
- Any controlled substance classification differences at the state level
Compounding Pharmacy Partners for Peptide Prescriptions
Choosing the right pharmacy partner is one of the most important decisions for a peptide therapy program. Here are pharmacies that Karpa Health integrates with for peptide prescribing:
Empower Pharmacy - One of the largest compounding pharmacies in the United States. FDA-registered 503A/503B facility with a broad peptide formulary. Direct-to-patient fulfillment.
Olympia Pharmacy - FDA-registered 503B outsourcing facility with peptide therapy formulations. Known for quality testing and documentation.
Strive Pharmacy - Personalized compounding pharmacy specializing in weight loss and hormone therapy compounds, including peptide formulations.
Belmar Pharma Solutions - National compounding pharmacy with expertise in BHRT, TRT, and specialty compounds including peptides.
BoomRx - Pharmacy fulfillment platform with a multi-pharmacy network, providing practices access to multiple compounding sources.
With a platform like Karpa, you can connect to multiple pharmacies and route prescriptions electronically with one click, rather than managing each pharmacy relationship manually.
Key Considerations Before Launching
Informed Consent
Peptide therapy patients should receive clear information about the experimental or off-label nature of many peptide applications. Your informed consent should cover the intended use, potential side effects, the fact that many peptide applications are not FDA-approved for the specific indication, and the patient’s right to decline treatment.
Patient Screening
Not every patient is a candidate for peptide therapy. Develop screening criteria that account for contraindications, drug interactions, pregnancy, and conditions that may make specific peptides inappropriate. Document your clinical rationale for each prescription.
Malpractice Coverage
Contact your malpractice insurance provider before launching a peptide program. Confirm that your policy covers prescribing compounded peptides and any telehealth consultations you plan to offer. Some carriers may require a rider or may have specific documentation requirements.
Documentation Standards
Maintain thorough documentation for every patient interaction, clinical decision, and prescription. This protects both you and your patients. Practices using structured EHR workflows and AI-assisted documentation can maintain high documentation standards without spending excessive time on paperwork.
Staying Current
The regulatory environment for peptides is evolving. Subscribe to FDA drug compounding updates, follow relevant medical associations, and periodically review your state board communications. The formal rule publishing will include specific compliance timelines that practices will need to follow.
How Karpa Helps Practices Launch Peptide Programs
Karpa Health is a turn-key platform that handles the operational infrastructure for peptide therapy programs so physicians can focus on patient care. The platform includes:
- Patient intake forms that embed directly on your practice website under your brand
- AI-powered clinical review that screens patients, flags contraindications, and prepares clinical summaries for physician approval
- One-click prescribing to integrated compounding pharmacies including Empower, Olympia, Strive, Belmar, and BoomRx
- Real-time order tracking and direct-to-patient fulfillment
- Automated patient follow-up with treatment reminders and reactivation campaigns
- White-label branding so patients never see Karpa
Most practices go live in under two weeks. The platform handles peptide therapy, GLP-1 weight loss, TRT, and HRT programs, so you can diversify your offerings from a single system.
Learn more about Karpa’s peptide therapy platform or book a demo to see how it works for your practice.
For more context on closely related topics, read peptide therapy legal guide, 503A vs. 503B pharmacy guide, and GLP-1 compounding regulations guide.
Book a call with Karpa Health if you want help structuring the right program.
